Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
Protocol ID
PNOC022
Disease (Sub Disease)
Diffuse Midline Glioma
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Location
NSW, QLD, VIC, WA, SA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
Trial Status
Open
Sites
The Children's Hospital at Westmead
Royal Children's Hospital
Queensland Children's Hospital
Perth Children's Hospital
Women's and Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
John Hunter Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
2 Years to 39 Years
International registry ID's
NCT05009992
Back to Registry
Study Title A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression
Protocol ID PNOC022
Disease (Sub Disease) Diffuse Midline Glioma
Diagnosis Stage Newly diagnosed
Relapsed/Refractory
Location NSW / QLD / VIC / WA / SA
Sponsor Australian and New Zealand Children's Haematology Oncology Group
Collaborators Pacific Pediatric Neuro-Oncology Consortium
Links https://clinicaltrials.gov/ct2/show/NCT05009992
Trial Status Open
Trial Open Date 18/08/2022
Sites The Children's Hospital at Westmead/ Royal Children's Hospital / Queensland Children's Hospital/ Perth Children's Hospital/ Women's and Children's Hospital/ Monash Children's Hospital/ Sydney Children's Hospital/ John Hunter Children's Hospital/
Study Type Treatment
Phase Phase 1/2
Age Eligibility 2 Years to 39 Years
International registry ID's NCT05009992